Line 38: |
Line 38: |
| | | | | |
| | Ganglioglioma | | | Ganglioglioma |
− | | Only 30% are abnormal by karyotype '''Gain:''' polysomy 7 | + | | Only 30% are abnormal by karyotype <br> |
| + | '''Gain:''' polysomy 7 |
| | '''Mutations:''' BRAF V600E in 20-60% of cases (can be concurrent with CDKN2A homozygous deletion)<br> | | | '''Mutations:''' BRAF V600E in 20-60% of cases (can be concurrent with CDKN2A homozygous deletion)<br> |
| '''Fusions:''' KIAA1549-BRAF | | '''Fusions:''' KIAA1549-BRAF |
Line 54: |
Line 55: |
| | | | | |
| | Pleomorphic xanthoastrocytoma (PXA) | | | Pleomorphic xanthoastrocytoma (PXA) |
− | | Polysomy 3, polysomy 7 observed; '''Loss:''' monosomy 9 / 9p deletion | + | | Polysomy 3, polysomy 7 observed<br> |
| + | '''Loss:''' monosomy 9 / 9p deletion |
| | '''Mutations:''' BRAF V600E in ~60%; TP53 (5%)<br> | | | '''Mutations:''' BRAF V600E in ~60%; TP53 (5%)<br> |
| '''Loss:''' CDKN2A/CDKN2B | | '''Loss:''' CDKN2A/CDKN2B |
Line 80: |
Line 82: |
| |IDH-mutant | | |IDH-mutant |
| |'''Gain:''' 1q, 2q, 3q, 7, 16p, 17q, 21q<br> | | |'''Gain:''' 1q, 2q, 3q, 7, 16p, 17q, 21q<br> |
− | '''Loss:''' 6q, 8q, 9p, 9q, 10q, 13q, 17p, 22q | + | '''Loss:''' 6q, 8q, 9p, 9q, 10q, 13q, 17p, 22q<br> |
| ''' Chromothripsis:''' observed | | ''' Chromothripsis:''' observed |
| |'''Loss:''' PTEN, RB1, TP53, CDKN2A/B/C | | |'''Loss:''' PTEN, RB1, TP53, CDKN2A/B/C |